Skip to content
value.today

Chembio Diagnostics

CEMIUnlisted company
$8 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

More about Chembio Diagnostics

Acquisitions and changes
No longer listed: ticker CEMI is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$26 M$52 M$78 M$104 M202020212022

World rank over time

▼ down 11,977 places since 2020
2020-01-01: #19792#19,79220202021-01-01: #18348#18,34820212022-01-07: #28702#28,70220222022-12-25: #31769#31,7692022

Rank in USA: #3,844 (Jan 2020) · #3,714 (Jan 2021) · #5,144 (Jan 2022) · #5,636 (Dec 2022)

Lobbying by Chembio Diagnostics#

$10 K spent on lobbying the US Congress and federal agencies in 2022, most often on manufacturing and medical/disease research/clinical labs.

Lobbying, 2022
$10 K
#1,371 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Manufacturing1 report
  • Medical/Disease Research/Clinical Labs1 report

Lobbying firms hired in 2022

K&L GATES LLP $10 K

Chembio Diagnostics: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$10 K—4
2021$40 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Chembio Diagnostics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Product recalls by Chembio Diagnostics#

1 recalls since 2015, 126 units in the notices that give a number. Medical devices (FDA): 1.

Chembio Diagnostics: product recalls
DateWhat and whyUnitsNotice
Chembio DPP¿ Micro Reader for use with the DPP¿ COVID-19 IgM/IgG System- Rapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in fingerstick whole blood, venous whole blood, serum, or plasma (lithium heparin or EDTA. Mode… (and 2 more products)FDA revocation of the Emergency Use Authorization due to performance issuesMedical devicesClass II126Z-2808-2020

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Chembio Diagnostics🇺🇸$8 M———
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Profile updated:
Nov 14, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Chembio Diagnostics? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Chembio Diagnostics's ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Chembio Diagnostics? Suggest a correction